Search

Your search keyword '"Patton, David R."' showing total 210 results

Search Constraints

Start Over You searched for: Author "Patton, David R." Remove constraint Author: "Patton, David R." Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
210 results on '"Patton, David R."'

Search Results

1. Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Childrenʼs Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)

2. Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D

3. Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

4. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Childrenʼs Oncology Group Pediatric MATCH Trial

5. The NCI-MATCH trial: lessons for precision oncology

6. Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

7. Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1

8. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

9. X-ray AGNs with SRG/eROSITA: multiwavelength observations reveal merger triggering and post-coalescence circumnuclear blowout.

10. Galaxy mergers in UNIONS – I. A simulation-driven hybrid deep learning ensemble for pure galaxy merger classification.

11. Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B

12. Interacting galaxies in the IllustrisTNG simulations – VI: Reconstructed orbits, close encounters, and mergers.

13. Interacting galaxies in the IllustrisTNG simulations – VII: the connection between the most luminous active galactic nuclei and galaxy interactions.

14. The limitations (and potential) of non-parametric morphology statistics for post-merger identification.

16. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.

17. Interacting galaxies in the IllustrisTNG simulations – V. Comparing the influence of star-forming versus passive companions.

18. AGNs in post-mergers from the ultraviolet near infrared optical northern survey.

19. Interacting galaxies in the IllustrisTNG simulations − IV: enhanced supermassive black hole accretion rates in post-merger galaxies.

20. The interconnection between galaxy mergers, AGN activity, and rapid quenching of star formation in simulated post-merger galaxies.

29. Galaxy mergers can rapidly shut down star formation.

30. ALMaQUEST Survey X: what powers merger induced star formation?

31. Galaxy pairs in the Sloan Digital Sky Survey – XV. Properties of ionized outflows.

32. Star formation characteristics of CNN-identified post-mergers in the Ultraviolet Near Infrared Optical Northern Survey (UNIONS).

33. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.

35. Phase II Study of Copanlisib in Patients With Tumors With Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.

36. combined and respective roles of imaging and stellar kinematics in identifying galaxy merger remnants.

40. Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.

41. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial.

42. Interacting galaxies in the IllustrisTNG simulations – III. (The rarity of) quenching in post-merger galaxies.

43. Spatially resolved star formation and fuelling in galaxy interactions.

44. Interacting galaxies in the IllustrisTNG simulations - I: Triggered star formation in a cosmological context.

45. Galaxy pairs in the Sloan Digital Sky Survey – XIV. Galaxy mergers do not lie on the fundamental metallicity relation.

46. Interacting galaxies in the IllustrisTNG simulations – II: star formation in the post-merger stage.

47. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.

48. definitive merger-AGN connection at z ∼ 0 with CFIS: mergers have an excess of AGN and AGN hosts are more frequently disturbed.

49. Interacting galaxies on FIRE-2: the connection between enhanced star formation and interstellar gas content.

50. What shapes a galaxy? – unraveling the role of mass, environment, and star formation in forming galactic structure.

Catalog

Books, media, physical & digital resources